Siemens' (SI) PETNET Signs to Distribute Lilly's (LLY) Molecular Inaging Agent
Tweet
Share
E-mailGet Alerts SI Hot Sheet
Join SI Premium – FREE
PETNET Solutions Inc., a wholly owned subsidiary of Siemens (NYSE: SI) Medical Solutions USA, Inc., has entered into a nationwide commercial agreement with Eli Lilly and Company (NYSE: LLY) that grants Siemens PETNET Solutions the right to manufacture and distribute Lilly's molecular imaging agent that is currently under review by the U.S. Food and Drug Administration (FDA) for positron emission tomography (PET) imaging.
Siemens PETNET Solutions is the first company to sign an agreement for the commercial manufacturing and distribution of Lilly's molecular imaging agent in the U.S., should it be FDA approved. Additionally, should Lilly's molecular imaging agent be approved in markets outside the U.S., the companies would consider expanding this commercial agreement to those markets as well.
Siemens PETNET Solutions is the first company to sign an agreement for the commercial manufacturing and distribution of Lilly's molecular imaging agent in the U.S., should it be FDA approved. Additionally, should Lilly's molecular imaging agent be approved in markets outside the U.S., the companies would consider expanding this commercial agreement to those markets as well.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Nu Skin EVP of global sales takes medical leave
- Boeing names Ryan Shedd as new SVP and controller
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
